<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069312</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00179281</org_study_id>
    <nct_id>NCT04069312</nct_id>
  </id_info>
  <brief_title>Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)</brief_title>
  <acronym>RELIANCE</acronym>
  <official_title>Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to&#xD;
      compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate&#xD;
      regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate&#xD;
      regimen) to prevent hospitalization or death in a patients at high risk for COPD&#xD;
      exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RELIANCE is a U.S.-based pragmatic clinical trial funded by the Patient-Centered Outcomes&#xD;
      Research Institute (PCORI) to compare long-term use of roflumilast vs. azithromycin in up to&#xD;
      3,200 patients. It is intended to support hospital efforts to reduce the risk of all-cause&#xD;
      hospitalization and reduce pre-mature deaths in individuals with chronic obstructive&#xD;
      pulmonary disease (COPD) who have been hospitalized in the prior year for a COPD&#xD;
      exacerbation. The COPD Patient Powered Research Network (PPRN) and affiliated investigators&#xD;
      will conduct the trial in sites in the U.S.&#xD;
&#xD;
      Both roflumilast and azithromycin have been shown to reduce the risk of COPD exacerbations&#xD;
      compared to placebo. However, there has not been a head-to-head comparison of the two&#xD;
      medications. So, the relative harms and benefits of the two medications are unknown. Eligible&#xD;
      patients will be randomized (1:1) to receive either a prescription for roflumilast or a&#xD;
      prescription for azithromycin, and will be followed for at least 6 and up to 36 months. The&#xD;
      primary endpoint is the combined outcome of all-cause hospitalization or death; the secondary&#xD;
      endpoints include premature treatment discontinuation, patient-reported adverse effects, and&#xD;
      physical, social, and emotional health. Patients will be enrolled at participating clinical&#xD;
      sites and follow up data will be collected via an online patient portal or via a call center.&#xD;
      Baseline and outcome data will also be collected from site medical records and&#xD;
      administrative/claims databases.&#xD;
&#xD;
      Pragmatic, non-inferiority trial using an intention-to-treat analysis to evaluate whether&#xD;
      daily azithromycin is non-inferior to daily roflumilast in patients at high risk of COPD&#xD;
      exacerbations. The investigators will randomize individual patients to receive prescriptions&#xD;
      for roflumilast or azithromycin (1:1 ratio), stratified by site and current smoking status&#xD;
      (yes/no).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial is a parallel, pragmatic non-inferiority trial with two treatment groups, roflumilast and azithromycin. Up to 3,200 participants will be randomized (1:1) to receive a prescription for one of the two treatments. Treatment assignments will be stratified by site and smoking status (former versus current) using a permuted block design with multiple block sizes.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Treatment assignments will be concealed prior to randomization. Once a patient is assigned to receive a treatment, the clinician, Site Coordinator and patient will not be masked. i.e., they will know the treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of All-cause hospitalizations</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All-cause hospitalizations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of All-cause deaths</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All-cause deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of All-cause individual events</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All-cause individual events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical function as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>Based on the scoring scale; a score of 5 is the most favorable and a score of 1 is least favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in problems with sleep as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>1 is least favorable and 5 is most favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>0 is most favorable and 4 and least favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>Score of 1 is most favorable and 5 is least favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>1 is most favorable and 5 is least favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence as assessed by patient self-report</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Medication Adherence will be assessed by self-report via Call Center or Patient Portal; Medicare claims data in a subset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that switch to alternate study medication</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Patient will be assigned either azithromycin or roflumilast at randomization. We will assess any switch to either roflumilast from azithromycin or azithromycin from roflumilast by self-report via Call Center or Patient Portal, query of clinic staff; Medicare claims data in a subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Out of pocket cost for study medication</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Out of pocket costs for roflumilast of azithromycin by self-report via Call Center or Patient Portal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Weight in lbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that discontinued medication</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>This will be collected by self-report via Call Center or Patient Portal; query of clinic staff; Medicare claims data in a subset</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease Severe</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Roflumilast arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months</description>
    <arm_group_label>Roflumilast arm</arm_group_label>
    <other_name>Daliresp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months</description>
    <arm_group_label>Azithromycin arm</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient and treating clinician considering treatment intensification with roflumilast&#xD;
             or azithromycin to reduce the risk of COPD exacerbations&#xD;
&#xD;
          -  Age â‰¥ 40 years&#xD;
&#xD;
          -  Current or past smoker of at least 10 pack-years&#xD;
&#xD;
          -  Diagnosis of severe COPD and associated chronic bronchitis&#xD;
&#xD;
          -  Hospitalized with a diagnosis of COPD exacerbation in the past 12 months&#xD;
&#xD;
          -  Current medications include inhaled Long Acting Muscarinic Antagonist (LAMA), Long&#xD;
             Acting Beta Agonist (LABA) /LAMA, or Inhaled Corticosteroids (ICS) /LABA&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or declines to provide informed consent;&#xD;
&#xD;
          -  Declines to provide social security number or health insurance claims number (as&#xD;
             applicable)&#xD;
&#xD;
          -  History of intolerance to azithromycin or roflumilast that the patient or patient's&#xD;
             treating clinician considers sufficiently serious to avoid either treatment option;&#xD;
&#xD;
          -  Current treatment with long-term (more than 30 days) roflumilast or azithromycin&#xD;
             (previous treatment with 1 or more doses of azithromycin or roflumilast is not an&#xD;
             exclusion criterion, as long as the patient and clinician are seeking treatment&#xD;
             intensification options and would be willing to use azithromycin or roflumilast, as&#xD;
             per randomized treatment assignment.)&#xD;
&#xD;
          -  Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide&#xD;
             antibiotic;&#xD;
&#xD;
          -  History of cholestatic jaundice/hepatic dysfunction associated with prior use of&#xD;
             azithromycin&#xD;
&#xD;
          -  Moderate to severe liver impairment (Child-Pugh B or C)&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Any other clinician-determined exclusion as per the clinician's clinical practice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Krishnan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois, Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Wise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gem Roy, MD</last_name>
    <phone>4432875796</phone>
    <email>groy2@jhu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Surya Bhatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lynn Gerald, PhD, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Avdalovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Hanley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ravi Kalhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valentin Centurion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore Hospital</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shashi Bellam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alejandro Comellas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonardo Seoane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nirupama Putcha, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Health</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victor Pinto-Plata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meilan Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Ouellette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gary Salzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sidney Braman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital/Northwell Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Roselli</last_name>
    </contact>
    <investigator>
      <last_name>Bushra Mina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Drummond, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Scialla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rodney Folz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Umur Hatipoglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Mularski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerard Criner, MD, FACP, FACCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Sciurba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charlie Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White (BSW) Health-North</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Millard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health and Services</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Allison Lambert, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valeriie Bonne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>COPD</keyword>
  <keyword>Roflumilast</keyword>
  <keyword>Daliresp</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

